Clinical Trial Update: This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including Lymphomas [Phase 1]

View source ↗

Summary

Phase 1 study of eribulin mesylate in pediatric participants with recurrent or refractory solid tumors (excluding CNS) and lymphomas completed; results posted i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphomas
• Or Refractory Solid Tumors
• Solid Tumors

Drugs mentioned

• ERIBULIN MESYLATE (Eribulin mesylate)

Snippet

Sponsor: Eisai Inc. | Conditions: Pediatrics, Solid Tumors | Phase 1 | Status: COMPLETED | Results posted: 2018-12-24